16th Aug 2021 17:57
(Alliance News) - Syncona Ltd on Monday said its portfolio company, Freeline Therapeutics Holdings PLC, reported that President & Chief Operating Officer Michael Parini has succeeded Theresa Heggie as chief executive officer.
In addition, following the departure of Freeline Chief Medical Officer Julie Krop, Alison Long, head of Clinical Development, will serve in the role of interim CMO while an external search for a new CMO is underway.
Freeline is a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases.
Freeline also reported that it is on track for three programs in the clinic by the end of 2021. The company intends to initiate trial site for FLT180a for Hemophilia B and FLT201 for Gaucher disease type 1, while program for FLT190 for Fabry disease is progressing.
FTSE 250-listed Syncona shares closed 1.1% lower in London on Monday at 212.75 pence each.
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Syncona